Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes : Episode 2
The Impact of Molecular Testing on Treatment Choices for NSCLC
A discussion with Dr. Garon highlights patient selection for EGFR inhibitor therapy in EGFR+ NSCLC, emphasizing the critical role of biomarker testing, testing approaches, and overcoming barriers in community settings.
EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC
Now Viewing
EP: 2.The Impact of Molecular Testing on Treatment Choices for NSCLC
EP: 3.Overview of FLAURA and MARIPOSA-2 Clinical Trials
EP: 4.Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
EP: 5.Factors in Selecting Treatment Options for EGFR+ NSCLC
EP: 6.Evaluating Treatment Options of EGFR Inhibitors
EP: 7.Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices
EP: 8.Jason’s Journey with ALK+ Metatstatic NSCLC
EP: 9.Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
EP: 10.Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
EP: 11.Overview of Current Treatment Landscape of ALK Inhibitors
EP: 12.Clinical Experience of Lorlatinib ALK+ NSCLC Patients
EP: 13.Patient Factors Considered when Choosing Treatment Selection
EP: 14.Treatment Strategies in Disease Progression in ALK+ NSCLC
EP: 15.Evaluating ALK Inhibitors in Treatment Sequencing and Testing
EP: 16.Future Therapies for ALK+ Metastatic NSCLC
Video content above is prompted by the following:
- What factors make this patient an ideal candidate for EGFR inhibitor therapy?
- How important is biomarker testing in guiding treatment choices for EGFR+ NSCLC?
- Can you share your approach to testing for EGFR mutations, and any barriers encountered, especially in community settings?
Recent Videos
